Studies whose primary subject is both MDMA and Depression, with an evidence synthesis read across the most-cited and most recent of them.
Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for MDMA, ecstasy, molly, methylenedioxymethamphetamine, Depression, major depressive disorder, then ranked by relevance.
Direct evidence on MDMA for depression is sparse and mostly indirect. A 2026 meta-analysis in PTSD found MDMA-assisted therapy may also improve depressive symptoms alongside PTSD, and a palliative-care review reports reductions in depression among seriously ill patients, but these are secondary outcomes in non-depression populations. For major depression specifically, the literature consists mainly of commentary and protocol papers calling for rigorous trials rather than completed efficacy data, so no confident conclusion about MDMA as a depression treatment can be drawn.
Direction is which way each study's own result points, not our rating of the study.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| MDMA-Assisted Therapy May Decrease PTSD Symptoms, Dissociation, Depression, and Functional Disability: A Systematic Review and Meta-Analysis 2026 | systematic review and meta-analysis | Supports | MDMA-assisted psychotherapy may significantly improve PTSD, dissociation, depression, and functional impairment compared with low-dose MDMA or placebo controls combined with psychotherapy, though evidence is limited by small samples, blinding challenges, non-standardized therapies, and a common sponsor. | |
| Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious Illness. 2022 | review | Supports | Psychedelic-assisted therapy, including one-time dosing, may lead to sustained reductions in anxiety, depression, and demoralization in seriously ill and end-of-life patients, though practical guidance for clinicians remains limited. | |
| Psychedelics for Patients With Cancer: A Comprehensive Literature Review 2023 | systematic review | Supports | Across five randomized, double-blind, placebo-controlled trials, psychedelics significantly reduced anxiety and depression in patients with cancer on several scales, though the studies had limitations. | |
| MDMA and MDMA-Assisted Therapy. 2025 | review | Supports | MDMA-assisted therapy in controlled clinical settings is reported as safe and efficacious for PTSD, with 67%-71% of individuals no longer meeting diagnostic criteria versus 32%-48% with placebo-assisted therapy, and effects enduring at long-term follow-up. | |
| 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial. 2018 | randomized controlled trial | 28 | Supports | Active doses of MDMA (100 mg and 125 mg) with psychotherapy produced larger reductions in PTSD symptoms than a low dose (40 mg), with statistical significance only in the per-protocol set, and 76% no longer met PTSD criteria at 12-month follow-up. |
| MDMA-assisted psychotherapy in major depression: critical considerations for clinical translation: commentary, Kvam et al. 2026 | commentary | Unclear | Argues that MDMA-assisted psychotherapy for major depression requires further rigorous study to address methodological and ethical concerns before clinical translation. | |
| MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study - CORRIGENDUM. 2026 | other | Unclear | A corrigendum for a proof-of-principle study on MDMA-assisted therapy for major depressive disorder; no abstract available. | |
| [The use of psychedelics in psychiatry]. 2026 | review | Mixed | Argues that psilocybin produces consistent improvements in major depressive disorder while MDMA-assisted psychotherapy has the largest phase 3 dataset in PTSD but was declined FDA approval in 2024 on ethical grounds, and that certainty of evidence remains low or very low for several indications. | |
| Role of Psychedelics in Treatment-Resistant Depression. 2023 | review | Unclear | Reports that evidence for classic psychedelics in treatment-resistant depression is limited but early studies show promising results, and notes the field may be subject to a hype bubble. | |
| Placebo Effects in the Treatment of Depression-Implications for the Psychedelic Renaissance. 2026 | review | Unclear | Argues that expectancy, therapeutic setting, and trial design shape placebo effects in depression trials, and that these factors are particularly relevant for evaluating psychedelic-like compounds. | |
| Past-year hallucinogen use in relation to psychological distress, depression, and suicidality among US adults. 2022 | observational cohort | 241675 | Supports | Past-year ecstasy use was associated with a decreased likelihood of serious psychological distress, major depressive episode, and suicidal thinking, while LSD use was associated with increased likelihood of these outcomes. |
| Major depression: the relative contribution of gender, MDMA, and cannabis use 2007 | cross-sectional study | 226 | No effect | No association was found between number of MDMA uses and lifetime Major Depressive Disorder; lifetime cannabis use disorder, but not MDMA use, was significantly associated with lifetime major depression. |
| Symptoms of anxiety and depression in childhood and use of MDMA: prospective, population based study 2006 | prospective longitudinal population-based study | 1580 | Opposes | Childhood symptoms of anxiety or depression significantly increased the risk of later MDMA use (hazard ratio 2.22), suggesting reverse-direction association rather than MDMA reducing depression. |
| R-MDDMA is a Safer Analogue of MDMA with Therapeutic Potential. 2026 | preclinical study | Supports | R-MDDMA, an MDMA analogue, promoted structural neuroplasticity, facilitated fear extinction learning, and produced sustained antidepressant-like effects without the abuse-related effects of MDMA. | |
| Investigating the Role of Self-Compassion in MDMA-Assisted Therapy for Social Anxiety Disorder 2026 | pre-registered study protocol | Unclear | A protocol to characterize self-compassion during MDMA-assisted therapy for social anxiety disorder and evaluate it as a mechanism of change, including associations with depressive symptoms. | |
| MDMA-assisted PTSD and Alcohol Therapy Trial (MPATHY): study protocol for a double-blind, randomised, controlled outpatient trial of MDMA-assisted integrated exposure-based therapy for comorbid post-traumatic stress disorder and alcohol use disorder 2026 | randomized controlled trial | 100 | Unclear | A protocol for a double-blind trial testing whether MDMA-assisted integrated exposure therapy improves PTSD and alcohol use outcomes versus active control-assisted therapy in comorbid PTSD and AUD. |
| Australia to prescribe MDMA and psilocybin for PTSD and depression in world first 2023 | news feature | Unclear | Reports that Australia's decision to prescribe MDMA and psilocybin for PTSD and depression was dogged by suggestions that it was rushed. | |
| Australia’s approval of MDMA and psilocybin for PTSD and depression is premature, say critics 2023 | news report | Unclear | Reports that Australia's TGA attached conditions to MDMA and psilocybin use, requiring authorized psychiatrists, ethics committee approval per patient, and use with psychotherapy, with critics calling the approval premature. | |
| Is it now time to prepare psychiatry for a psychedelic future? 2024 | review | Unclear | Argues that Australia's rescheduling of psilocybin and MDMA as treatments for treatment-resistant depression and PTSD creates both opportunities and challenges for psychiatry and health systems. | |
| MDMA and Psilocybin-Assisted Therapy in Australia: Early Real-World Prescribing, Safety Monitoring and Regulatory Developments 2026 | review | Unclear | Reports that Australia's regulatory pathway for MDMA and psilocybin prescriptions has grown rapidly but remains at an early stage, with authorized prescribers representing about 1% of the psychiatric workforce. | |
| Registered clinical studies investigating psychedelic drugs for psychiatric disorders. 2021 | review | 70 | Unclear | As of December 2020, 70 registered trials investigate psychedelics for psychiatric disorders, mostly MDMA and psilocybin for PTSD and major depressive disorder, with only 21 having published results. |
| The Use of Psychedelics in the Treatment of Medical Conditions: An Analysis of Currently Registered Psychedelics Studies in the American Drug Trial Registry. 2022 | systematic review | 105 | Unclear | Registered psychedelic trials have increased, most are early phase, and common disorders studied include substance addiction, PTSD, and major depressive disorder, with potential gaps in treatment-resistant depression. |
| Group psychedelic therapy: empirical estimates of cost-savings and improved access 2023 | comparative cost analysis using trial data and published estimates | Supports | Group psychedelic-assisted therapy reduced clinician costs by 50.9% for MDMA-PTSD and 34.7% for psilocybin-MDD, potentially saving billions and reducing clinician demand. | |
| Attitudes toward psychedelics and psychedelic-assisted therapy among potential mental health service users and the general population in Australia. 2024 | cross-sectional survey | 502 | Mixed | 43% favored legalizing psychedelics for medical use and 52.4% were open to their use, but only 24% viewed their effects positively and 33% considered them safe; attitudes were predicted by experience and knowledge. |
| The Serotonin 2B (5‐ HT2B ) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression 2026 | narrative review | Unclear | Argues that peripheral 5-HT2B receptor agonism is linked to valvular heart disease, with supportive but limited data for MDMA, while centrally selective antagonism is a potential augmentation target for treatment-resistant depression. |
This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is MDMA for depression, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.
A study qualifies only when MDMA for depression or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.
The full method, including what a person does and does not review, is on the methods page.
49 articles · 22 from the last two years · 246,836 participants across 19 studies reporting sample size
48 studies whose primary subject is MDMA for depression since 2004
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 0 |
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 0 |
| 2009 | 0 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 0 |
| 2013 | 0 |
| 2014 | 0 |
| 2015 | 0 |
| 2016 | 0 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 0 |
| 2020 | 0 |
| 2021 | 2 |
| 2022 | 5 |
| 2023 | 5 |
| 2024 | 5 |
| 2025 | 11 |
| 2026 | 10 |
Orvosi hetilap September 13, 2026 Szabolcs Kéri
Over the past five years, the literature on the psychiatric use of psychedelic and related treatments has expanded substantially. Several randomized controlled trials and pooled analyses have been conducted in mood disorders, treatment-resistant depression, and post-traumatic stress disorder. Trial methodology, however, remains a fundamental source of uncertainty, and despite the popularity of...
Harvard Review of Psychiatry September 8, 2026 Warwick M. Green, Sanket B Raut, F. E. James et al.
There is a need for new effective treatment options for posttraumatic stress disorder (PTSD), as many people with PTSD do not fully recover despite current treatments. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy (MDMA-AT) is emerging as a new treatment option. We assessed the current body of MDMA-AT evidence for effectiveness in treating PTSD, associated impairments, and...
July 12, 2026 Octavian Brinzei
Australia became the first country to establish a national regulatory pathway permitting authorised psychiatrists to prescribe 3,4-methylenedioxymethamphetamine (MDMA) for post-traumatic stress disorder (PTSD) and psilocybin for treatment-resistant depression (TRD) through the Therapeutic Goods Administration (TGA) Authorised Prescriber Scheme. Two and a half years after implementation,...
BMJ Open July 1, 2026 Kirsten Morley, Shalini Arunogiri, Katherine L. Mills et al.
INTRODUCTION: The treatment of comorbid post-traumatic stress disorder (PTSD) and alcohol use disorder (AUD) is significantly more challenging than the treatment of either disorder alone. While gold standard evidence-based treatments exist for this comorbidity, clinically significant improvements are only observed in approximately half of clinical trial participants. The use of adjunctive...
Clinical Pharmacology & Therapeutics May 28, 2026 Gia Han Le, Sabrina Wong, Danica E. Johnson et al.
Major depressive disorder (MDD) and treatment-resistant depression (TRD) remain leading causes of disability, providing the impetus for receptor-level treatment strategies beyond monoamine reuptake. The serotonin 5-HT2B receptor (5-HT2BR) is uniquely positioned at the interface of central-antidepressant mechanisms and peripheral cardiac risks. Herein, we reviewed preclinical, translational and...
ACS Chemical Neuroscience May 6, 2026 Maxemiliano V. Vargas, Cassandra J. Hatzipantelis, Lee E. Dunlap et al.
Recent clinical evidence suggests that racemic 3,4-methylenedioxymethamphetamine (MDMA) might be useful for treating a range of neuropsychiatric diseases including post-traumatic stress disorder (PTSD) and depression. However, concerns about its abuse potential stemming from its monoamine releasing properties have hampered its clinical development. Thus, safer analogues of racemic MDMA with...
Br J Psychiatry February 10, 2026 Tor-Morten Kvam, Ivar W Goksøyr, Justyna Rog et al.
An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.
Neurologic Clinics February 1, 2026 Mina Ansari, Sophie I Elliott, Sophie E Holmes et al. 1 citation
The development of novel, rapid-acting treatments and the resurgence of interest in the therapeutic potential of psychedelic-like compounds has stimulated excitement and enthusiasm within the pharmaceutical industry, and provided new hope for millions of individuals suffering with mental illness such as major depressive disorder and post-traumatic stress disorder. This review summarizes the...
Open Science Framework 2026 Christina Chwyl, M. Kati Lear, Sunjeev K. Kamboj et al.
Self-compassion is theorized to play a central role in promoting mental health and wellbeing, including for individuals with social anxiety disorder (SAD). One proposed mechanism of MDMA-assisted therapy (MDMA-AT) for SAD is the cultivation of self-compassion. Across five aims, we will characterize self-compassion experiences during MDMA-AT and evaluate its role as a potential mechanism of...
Journal of Clinical Medicine December 29, 2025 Monika Dominiak, Adam Gędek, Szymon Modrzejewski et al. 2 citations
Background: Psychedelic-assisted therapy is gaining renewed attention as a potential treatment for various mental disorders. Despite increasing numbers of randomized controlled trials (RCTs) and meta-analyses, a comprehensive synthesis of the evidence across different substances and indications is lacking. This umbrella review aims to evaluate the effectiveness and safety of...
Completed 759 participants Indiana University